Item 1.02. Termination of a Material Definitive Agreement.
On
Item 2.01. Completion of Acquisition or Disposition of Assets.
The Offer and withdrawal rights expired as scheduled at 12:00 midnight, Eastern
Time, at the end of the day on
--------------------------------------------------------------------------------
On
At the effective time of the Merger (the "Effective Time") and pursuant to the terms and conditions of the Merger Agreement, each outstanding Share, other than any Shares owned by Parent, Purchaser, or the Company or any of their respective wholly owned subsidiaries, or by stockholders who have validly exercised their appraisal rights under the DGCL, was canceled and converted into the right to receive an amount in cash equal to the Offer Price, payable to the holder thereof on the terms and subject to the conditions set forth in the Merger Agreement.
Each stock option outstanding immediately prior to the Effective Time, whether or not vested, became fully exercisable immediately prior to the Effective Time. To the extent not exercised prior to the Effective Time, each stock option was converted into the right to receive (subject to applicable withholding) the excess, if any, of the Offer Price over the exercise price per share of the stock option, multiplied by the number of Shares subject to the stock option. Except as provided in the Merger Agreement, each restricted stock unit outstanding immediately prior to the Effective Time was automatically accelerated and vested in full and was canceled and the holder became entitled to receive the Offer Price (subject to applicable withholding) multiplied by the number of Shares subject to such restricted stock unit. Except as provided in the Merger Agreement, each market-based stock unit outstanding immediately prior to the Effective Time vested based on the performance level attained pursuant to the terms of the applicable award agreement, including provisions relating to the effect of a change of control, and was canceled and the holder became entitled to receive the Offer Price (subject to applicable withholding) multiplied by the number of Shares subject to such market-based stock unit. The . . .
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
In connection with the closing of the Merger, the Company notified
Item 3.03. Material Modification to Rights of Security Holders.
The information set forth in the Introduction, Items 2.01, 3.01, 5.01 and 5.02 of this Current Report on Form 8-K is incorporated herein by reference to this Item 3.03.
Item 5.01. Changes in Control of Registrant.
As a result of Purchaser's acceptance for payment of all Shares that were
validly tendered and not properly withdrawn in accordance with the terms of the
Offer, a change of control of the Company occurred on
--------------------------------------------------------------------------------
The information disclosed under Items 2.01 and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In accordance with the terms of the Merger Agreement, the directors of Purchaser
immediately prior to the Effective Time,
Item 5.03. Amendment to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
Pursuant to the terms of the Merger Agreement, at the Effective Time, the certificate of incorporation and bylaws of the Company were amended and restated in their entirety in the forms filed as Exhibits 3.1 and 3.2 hereto, respectively, which are incorporated by reference herein.
Item 8.01. Other Events.
On
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. 2.1 Agreement and Plan of Merger, dated as ofMarch 12, 2021 , amongGenMark Diagnostics, Inc. ,Roche Holdings, Inc. andGeronimo Acquisition Corp. (incorporated by reference to Exhibit 2.1 of the Company's Current Report on Form 8-K filed with theSEC onMarch 15, 2021 ). 3.1 Amended and Restated Certificate of Incorporation ofGenMark Diagnostics, Inc. 3.2 Second Amended and Restated Bylaws ofGenMark Diagnostics, Inc. 99.1 Joint Media Release issued by Roche and GenMark, datedApril 22, 2021 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source